AU · rank #2 · 2026-10-20
ATEC
NASDAQ · $1.74B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.904 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.01 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $1,013,150 across 1 unique buyers. | 3.000 |
| Analyst upside Consensus target $15.79 | +51.6% |
| Momentum acceleration 3-month minus 12-month momentum. | +37.37% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.79 |
| Gross margin TTM | +70.8% |
| 52w high | $23.29 |
| Market cap (USD) | $1.74B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Alphatec Holdings is a medical technology company specializing in surgical spine solutions, integrating implants, biologics, EOS full-body imaging, EOS Insight software, SafeOp neuromonitoring, and the Valence navigation and robotics platform.
Rationale
The quant model's 51.6% analyst upside and 100% net positive revisions are supported by management raising 2026 adjusted EBITDA guidance to $140 million, 15% Q2 revenue growth, 24% net-new surgeon adoption, and over $1 million in insider buying.
Material risks
- 1Well-capitalized competitors like Medtronic, Globus Medical, and Stryker could replicate or bundle competing imaging, software, and robotic platforms to displace Valence and EOS Insight without ATEC holding an exclusive sole-source position.
- 2A heavy debt load of $510.7 million relative to $119 million in cash leaves limited capital flexibility if surgeon adoption, revenue per case, or free cash flow conversion falter.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.